Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617

The purpose of this study was to identify previous treatments and biomarker profile features that prognosticate overall survival (OS) in patients with mCRPC receiving (177)Lu-PSMA-617. Methods: 109 mCRPC patients treated with a median of 3 cycles of (177)Lu-PSMA-617 were included. Data were analyzed...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Theranostics
Asıl Yazarlar: Kessel, Katharina, Seifert, Robert, Schäfers, Michael, Weckesser, Matthias, Schlack, Katrin, Boegemann, Martin, Rahbar, Kambiz
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ivyspring International Publisher 2019
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6691377/
https://ncbi.nlm.nih.gov/pubmed/31410185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.35759
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller